-
Capital, M&A & Industry Strategy1 week agoIonis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
-
Capital, M&A & Industry Strategy1 week agoPfizer punts Seagen ADC, further muddying value of the $43B buyout
The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as...
-
Capital, M&A & Industry Strategy1 week agoSuperluminal Medicines secures $60m to advance rare obesity therapy
The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli...
-
Capital, M&A & Industry Strategy1 week agoStrong IP ecosystems drive biotech R&D and investment, report shows
Stronger intellectual property protection statistically correlates with increased development of cutting-edge therapies and greater investment in life sciences research, according to a closely watched […] The...
-
Capital, M&A & Industry Strategy1 week agoGSK wagers up to $1.3B on a different kind of cancer drug
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
-
Capital, M&A & Industry Strategy1 week agoTScan cuts 75% of workforce while shifting focus to solid tumor program
TScan Therapeutics is looking for strategic partnerships for its heme and autoimmune programs while working to advance two in vivo T cell therapy candidates into investigational...
-
Capital, M&A & Industry Strategy1 week agoSTAT+: Abivax has still not been acquired. What’s going on?
Biotech M&A activity is off the charts, yet the French drugmaker Abivax hasn't been picked up yet. There may be some explanations.
-
Capital, M&A & Industry Strategy1 week agoBreaking borders: Building biotech scale in Benelux
In this episode of Denatured, you’ll hear from Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We...
-
Capital, M&A & Industry Strategy1 week agoNovartis signs deal with Alteogen for drug delivery
The deal allows Novartis to exercise multiple options for exclusive global rights to develop subcutaneous versions of several of its products employing the berahyaluronidase alfa enzyme,...
-
Capital, M&A & Industry Strategy2 weeks agoFollow the money: How funding announcements can help identify jobs before they’re posted
Funding announcements can signal future hiring activity, giving biotech professionals a chance to build relationships before positions are posted. Industry experts share how to identify the...
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
